LGND Ligand Pharmaceuticals Incorporated
$286.85
Ligand Pharmaceuticals Incorporated (LGND) Earnings News
Earnings press releases, previews and reviews for Ligand Pharmaceuticals Incorporated (LGND), newest first. Our most recent is review: Ligand's Royalty Engine Drives a Clean EPS Beat and Second Guidance Raise, but Held Revenue Outlook and a Heavier Balance Sheet Temper the Story.
Thursday
October 29, 2026
11:21 AM ET
Ligand's Royalty Engine Drives a Clean EPS Beat and Second Guidance Raise, but Held Revenue Outlook and a Heavier Balance Sheet Temper the Story
Earnings Whispers · Review
Thursday
October 29, 2026
7:00 AM ET
Ligand Reports Third Quarter 2026 Financial Results
Thursday
October 22, 2026
4:01 PM ET
Ligand to Host Investor Day on December 8, 2026
Wednesday
October 21, 2026
1:14 PM ET
Ligand's First Clean Look at Zoma Tests a Raised Profit Floor Wall Street Hasn't Matched
Earnings Whispers · Preview
Thursday
October 15, 2026
7:00 AM ET
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
Thursday
August 6, 2026
7:00 AM ET
Ligand Reports Second Quarter 2026 Financial Results
Thursday
July 23, 2026
7:00 AM ET
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
Tuesday
July 14, 2026
9:00 AM ET
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
Wednesday
June 10, 2026
7:00 AM ET
Ligand Announces 2026 Investor Day in New York City